Chronic hepatitis B virus (HBV) infection imposes a severe burden on global public health.
Currently, there are no curative therapies for millions of chronic HBV-infected patients …

Chronic hepatitis B virus (HBV) infection remains a major health burden worldwide for which
there is still no effective curative treatment. Interferon (IFN) consists of a group of cytokines …

Human hepatitis B virus (HBV) is a small enveloped DNA virus with a complex life cycle. It is
the causative agent of acute and chronic hepatitis. HBV can resist immune system …

Chronic hepatitis B virus (HBV) infection remains a major challenge for clinicians, as there
are only two types of approved therapies: interferon-alpha (IFN-α) or its pegylated form, Peg …

Hepatitis B virus (HBV) infection is one of the major causes of liver diseases, affecting more
than 350 million people worldwide. The interferon (IFN)-mediated innate immune responses …

Hepatitis B virus infections have always been associated with high levels of mortality. In
2019, hepatitis B virus (HBV)-related diseases resulted in approximately 555,000 deaths …

HBV infection remains a leading cause of death worldwide. IFN-α inhibits viral replication in
vitro and in vivo, and pegylated IFN-α is a commonly administered treatment for individuals …

Background and Aims Interferon (IFN)‐α, composed of numerous subtypes, plays a crucial
role in immune defense. As the most studied subtype, IFN‐α2 has been used for treating …

IFN-lambda (IFNλ) is a member of the type III IFN family and is reported to possess anti-
pathogen, anti-cancer, and immunomodulatory properties; however, there are limited data …

Chronic infection with HBV is a major cause of advanced liver disease and hepatocellular
carcinoma. Nucleos (t) ide analogues effectively control HBV replication but viral cure is …